Drug Profile
Mivavotinib - Takeda Oncology
Alternative Names: CB-659; TAK-659Latest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator Millennium
- Developer Children's Cancer Research Institute; National Cancer Institute (USA); Northwestern University; RTI International; Takeda Oncology
- Class Amines; Antineoplastics; Cyclohexanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Phase I/II Acute myeloid leukaemia
- Preclinical Lymphoid leukaemia
- No development reported Gastric cancer; Head and neck cancer; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 04 Apr 2023 Calithera Biosciences terminates a phase II trial in diffuse large B-Cell lymphoma in the US as per the sponsors decision (NCT05319028)
- 10 Jun 2022 Phase-II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, In adults, In the elderly) in USA (PO) (NCT05319028)
- 31 Mar 2022 Preclinical pharmacodynamic data in Diffuse large B cell lymphoma released by Calithera